^
    Back
    Association details:
    Biomarker:TNIP2-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Lung Cancer
    Title:

    The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma

    Excerpt:
    The IHC analysis revealed an ALK-positive tumor, while NGS detected a TNIP2-ALK fusion. The patient achieved continuous remission after treatment with crizotinib...This case provides valuable information on the response to crizotinib of patients with TNIP2-ALK fusion...
    DOI:
    10.1016/j.lungcan.2019.08.032